Cancer Archives

servier sorrento pd 1 biotech chemo car t cancer

News and Trends 13 Jul 2016

French Pharma licenses California PD-1 Cancer Antibody for €710M

San Diego’s Sorrento Therapeutics has bagged a quarter-billion euro deal with Servier. The French Pharma giant will develop Sorrento’s PD-1 targeting platform – a key checkpoint inhibitor in Immuno-Oncology. Sorrento’s proprietary G-MAB library platform was used to identify and generate STI-A1110, an antibody which targets PD-1, one of the key targets in the rapidly developing immuno-oncology therapy […]

July 13, 2016 - 2 minutesmins - By Dani Bancroft

ono pharmaceutical biotech celyad cancer nk cell therapy

News and Trends 12 Jul 2016

Unique Natural Killer T-Cell Therapy secures €282M in Japan Deal

Belgian Celyad granted an exclusive license to Osaka based ONO Pharmaceutical for the development and commercialisation of Celyad’s unique allogeneic cell therapy in Japan, Korea and Taiwan. This license agreement opens new markets to Celyad and its NKR-2 T-cell cancer immunotherapy. In addition to a deal worth up to €282M, Celyad will also receive double digit royalties based on […]

July 12, 2016 - 3 minutesmins - By Dani Bancroft

cormorant interleukin 8 bms immuno oncology

News and Trends 7 Jul 2016

BMS to acquire Swedish Immuno-Oncology Biotech for €460M

Bristol-Myers Squibb wants to strengthen its immuno-oncology even further. For this, it is acquiring Cormorant – a Biotech developing immunotherapies in a deal that could go up to €460M. Based at the Karolinska Institute Science Park in Stockholm (Sweden), Cormorant was a private Biotech focusing on cancer immunotherapies. Its main program was HuMax-IL8, which is currently in Phase […]

July 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

cinfa amgen biosimilar biotech neutropenia chemotherapy

News and Trends 5 Jul 2016

Spanish Biotech gets New Milestone in Biosimilar Race with Amgen

The Spanish Cinfa Biotech’s race to compete with Amgen’s blockbuster for Chemotherapy-induced Neutropenia continues: the Neulasta biosimilar passes Phase I trials. Neulasta (pegfilgrastim) is a slightly longer acting version of Amgen’s other blockbuster Neupogen (the template for the first ever US approved biosimilar – from Novartis), the combined sales of which account for over 30% of Amgen’s income. […]

July 5, 2016 - 2 minutesmins - By Dani Bancroft

bristol myers squibb immunooncology cancer opdivo psioxus

News and Trends 1 Jul 2016

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Oxfordshire based PsiOxus will team up with the Immuno-Oncology Giant, Bristol-Myers Squibb, to test the combinatorial effect of their blockbuster drug with an Oncolytic viral therapy in late-stage cancer patients. Together they will evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ Enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Opdivo blockbuster (nivolumab), which […]

July 1, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 30 Jun 2016

Key German Hospital to start a Phase I trial in TCR Cell Therapy

Medigene will make its clinical debut in TCR, in a collaboration with the Max Delbrück Centre and the Charité Hospital in Berlin. The planned Phase I trial focus on the blood cancer multiple myeloma. Based near Munich (Germany), Medigene develops different anti-cancer cell therapies, as we recently discussed in an interview with former CFO […]

June 30, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 28 Jun 2016

And now, Immuno-oncology gets EMA’s pre-approval for Lung Cancer

MSD has received EMA pre-approval for its famous anti-PD-1 therapy, Keytruda. It could soon be used to treat non-small cell lung cancer (NSCLC), the deadliest type of cancer. Checkpoint inhibitors are a key strategy in the hype field of immuno-oncology. This kind of cancer therapy blocks the natural ‘safety checks’ of the immune system – […]

June 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

molmed graft host disease zalmoxis leukemia

News and Trends 28 Jun 2016

Will the Leading Italian Biotech soon have its First Cell therapy on the Market?

MolMed has received conditional market approval for Zalmoxis, an ex vivo genetically engineered cell therapy that stops immune rejection of transplanted hematopoietic stem cells. This is a big step forward in a key treatment for blood cancers. A transplant of hematopoietic stem cells (cells that give origin to blood cells) is often used as part of treatments for […]

June 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 27 Jun 2016

Genticel is facing hard Times Again!

As presented last week, Genticel was getting back on track with the announcement of two major milestones with the aim to prepare the phase III. However, the major outcomes of its Phase II were expected to be presented on the 17th of June at Eurogin 2016 Congress… Here they are (and they are really bad)! GTL001 is […]

June 27, 2016 - 2 minutesmins - By Jerome Topsent

biotech of the week volitionrx belgium 1213x418

News and Trends 24 Jun 2016

Cost-effective diagnostics for cancer? Only with VolitionRx!

Aberdeen, we say goodbye to you! We’re leaving Scotland this week and are heading down to Belgium. Besides being the place where most of the European Union action happens, Belgium also has a strong and interesting biotech scene. That’s why in Namur we’re visiting VolitionRx, our Biotech of the Week. City: Namur (Belgium) Founded: 2010 Employees: 11-50 employees […]

June 24, 2016 - 1 minutemin - By Joachim Eeckhout

News and Trends 23 Jun 2016

Cellectis gets paid for a first Milestone, Investors are pleased

After successfully ‘saving’ two babies with terminal-stage acute Leukemia, Cellectis finally treated the first patient in its Phase I trial. A major milestone that could confirm the potential of its lead candidate UCART-19. It’s once again a success for the French biotech company! As it announced on Monday, the first patient has been treated in […]

June 23, 2016 - 2 minutesmins - By Jerome Topsent

News and Trends 22 Jun 2016

What is Microsoft doing with this French Precision Medicine Biotech?

Median Technologies is partnering up with software giant Microsoft to integrate big data into its oncology imaging systems – and deliver Precision Medicine from the cloud. Medical imaging is an important part of the rise of digital medicine. Cool projects in the field include the aortic graft simulation of EVARplanning (one of the startups at Italian incubator […]

June 22, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

French Pharma licenses California PD-1 Cancer Antibody for €710M

Unique Natural Killer T-Cell Therapy secures €282M in Japan Deal

BMS to acquire Swedish Immuno-Oncology Biotech for €460M

Spanish Biotech gets New Milestone in Biosimilar Race with Amgen

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Key German Hospital to start a Phase I trial in TCR Cell Therapy

And now, Immuno-oncology gets EMA’s pre-approval for Lung Cancer

Will the Leading Italian Biotech soon have its First Cell therapy on the Market?

Genticel is facing hard Times Again!

Cost-effective diagnostics for cancer? Only with VolitionRx!

Cellectis gets paid for a first Milestone, Investors are pleased

What is Microsoft doing with this French Precision Medicine Biotech?

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!